ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2975

Journal of Clinical & Experimental Pathology received 2975 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

MicroRNA-29a drives DNA hypermethylation and metastasis of hepatocellular carcinoma by targeting TET family members

4th International Conference and Exhibition on Pathology

Zhi Dai, Qing Chen, Dan Yin, Xue-Dong Li, Kai Zhu, Shao-Lai Zhou, Jie Hu, Dong-Mei Gao, Zheng Wang, Ying-Hong Shi, Yong-Sheng Xiao, Jia Fan and Jian Zhou

ScientificTracks Abstracts-Workshop: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.016

Abstract
Background & Aims: Ten eleven translocation (TET) enzymes convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and play crucial roles in biological and pathological processes by mediating DNA demethylation; however, the functional role of this epigenetic mark and the related enzymes in hepatocellular carcinoma (HCC) progression remains unknown. Methods: We analyzed 5-hmC levels using tissue microarray from a 323 HCC patient cohort. We determined RNA expression levels of TET family proteins, the TET expression-silencing microRNA-29a, and suppressor of cytokine signaling 1 (SOCS1) in 108 HCC patients. The methylation status of SOCS1 promoter was examined using glucosylation of genomic 5-hmC followed by methylation sensitive polymerase chain reaction (glucMS-qPCR). We determined miR-29a and TET family membersā?? functional effects using RNA interference and transgenic expression in HCC cells and evaluated xenograft tumor growth in nude mice. Results: TET family enzymes down regulation is one likely mechanism underlying 5-hmC loss in HCC. There was a significant inverse correlation between miR-29a and TET expression in HCC tissues. Dot blot assay revealed that miR-29a up regulation and down regulation in HCC cells yields distinct global DNA hydroxymethylation patterns, and that increased DNA methylation of SOCS1 promoter is associated with miR-29a overexpression in HCC cells. Furthermore, miR-29a silencing anti-metastatic SOCS1 through direct TET family targeting, resulting in SOCS1 promoter demethylation inhibition. Finally, miR-29a overexpression correlates with poor clinical outcomes and TET-Family-SOCS1-matrix metalloproteinase (MMP) 9 axis silencing in HCC patients. Conclusions: These findings demonstrate that 5-hmC loss is an epigenetic hallmark of HCC, and miR-29a is an important epigenetic modifier, promoting HCC metastasis through TET family targeting. Moreover, these results offer a new strategy for epigenetic cancer therapy.
Biography
Top